Therefore, these findings provide insights into the molecular basis of the acquisition of mesenchymal plasticity and immune evasiveness by PDAC and CRC via augmentation of the RNA-binding protein Arid5a, and indicate that Arid5a is a promising target for tumor immunotherapy, in addition to inflammatory diseases (Figure 4). This evidence concerns the gene ARID5A and neoplasm.